all report title image
  • To Be Published : Nov 2023
  • Code : CMI2261
  • Pages : N/A
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Prophylactic human vaccines stimulate the immune response and are intended for ameliorating the effects of future infection caused by pathogens in human beings. Novel vaccine development technologies such as viral-like particles are used in developing Hepatitis B Virus (HBV) vaccines, and Human Papilloma Virus (HPV) vaccines. For instance, in March 2014, CureVac AG received EUR 2 million Vaccine Prize from European Commission for its novel RNActive vaccine technology. This RNActive vaccine technology enables production of safe, efficacious, and cost-effective vaccines that are protected against elevated temperature as well as inadvertent freezing.

Prophylactic Human Vaccine Market – Drivers

Increasing number of pipeline studies and rising involvement of key players for vaccine development is expected to propel growth of the prophylactic human vaccine market during the forecast period. For instance, in October 2018, CureVac AG, announced to initiate dose escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. This will enable vaccinated individual's own cells to produce RABV-G protein, by which immune response gets triggered. This study is estimated to complete in January 2021.

Moreover, in October 2018, Valneva SE announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya. It is designed for prophylactic, active, single-dose immunization against Chikungunya in humans. The vaccine aims for long-lasting protection and an anticipated safety profile similar to other approved vaccines for active immunization in adults and children.

Furthermore, rising initiatives by various scientists to develop innovative solutions to fight against infectious diseases is expected to drive growth of the market. For instance, VBI Vaccines Inc., in September 2018, announced formation of three Scientific and Clinical Advisory Boards (SABs) comprising leading experts in infectious disease and immuno-oncology research and vaccine development targeting hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). This collaboration is expected to propel growth of the market, owing to enhanced vaccine development.

Prophylactic Human Vaccine Market – Restraint

Significant barriers in the vaccine development such as virus diversity and limited number of animal models are estimated to hamper growth of the prophylactic human vaccine market. For instance, according to Gastroenterology, in October 2018, vaccine development requires huge investment from various resources and is very challenging. Designing vaccine trials in human is difficult since following immunization the chances for develop an acute infection is very high. Therefore, anti-viral treatment has to be offered immediately, which makes it a challenging task to manage disease.

Prophylactic Human Vaccine Market – Regional Analysis

On the basis of region, the global prophylactic human vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is probable to lead in the global prophylactic human vaccine market, owing to receiving large number of research grants by government. For instance, in September 2018, GeoVax Labs, Inc., U.S.-based company recieved grant of US$ 2,442,307 by the U.S. Army Medical Research Acquisition Activity. The grant was awarded as a cooperative agreement for novel Lassa Fever (LF) vaccine (GEO-LM01) development program. GEO-LM01 uses Modified Vaccinia Ankara (MVA) and Virus-Like Particle (VLP) vaccine platform that has been demonstrated to be safe and induce antibody responses in patients. Moreover, MVA-VLP platform has shown effective results in other cases such as GeoVax’s prophylactic HIV vaccine, GeoVax’s Ebola (EBOV) vaccine, and GeoVax’s Zika vaccine in its respective preclinical studies.

Europe region is also expected to perceive extensive growth in prophylactic human vaccine market, due to rising initiatives by government for developing efficient and safe vaccines. For instance, in October 2017, the European Commission funded TRANSVAC, a new infrastructure project. This project aims to rapidly develop effective vaccines in order to address European health challenges and in turn increase the sustainability of EC vaccine projects in Europe. TRANSVAC offers high-quality technical services to support development of prophylactic and therapeutic vaccines for both human and animal use.

The key players operating in prophylactic human vaccine market include, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.

Prophylactic Human Vaccine Market – Taxonomy

By Vaccine Technology

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Polysaccharide Vaccines
  • Conjugate Vaccines
  • Recombinant Vaccines

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo